Last reviewed · How we verify
NCT04809181
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Phase 2 trial testing Azacitidine in Combination With Venetoclax in Hematologic Malignancy in 95 participants. Status unknown.
19 March 2024
Quick facts
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 95 |
| Start date | 19 March 2021 |
| Primary completion | 19 March 2024 |
| Estimated completion | 19 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Azacitidine in Combination With Venetoclax — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
Sponsor
First Affiliated Hospital of Zhejiang University
Who can join
Adults 18 to 65, any sex, with Hematologic Malignancy or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell transplantation for AML/MDS.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The clinical impact of the molecular landscape of acute myeloid leukemia.
Kayser S, Levis MJ. · · 2023 · cited 91× · PMID 36722402 · DOI 10.3324/haematol.2022.280801 -
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL, Ravandi F, Patel KP, Short NJ. · · 2021 · cited 40× · PMID 34479626 · DOI 10.1186/s13045-021-01148-5 -
PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Kontandreopoulou CN, Diamantopoulos PT, Tiblalexi D, Giannakopoulou N, et al · · 2021 · cited 26× · PMID 34529761 · DOI 10.1182/bloodadvances.2021004638 -
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A, Konopleva MY. · · 2022 · cited 19× · PMID 35072368 · DOI 10.1097/ppo.0000000000000567 -
Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.
Chang YJ, Zhao XY, Huang XJ. · · 2021 · cited 15× · PMID 34778077 · DOI 10.3389/fonc.2021.758512 -
Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
Abou Dalle I, El Cheikh J, Bazarbachi A. · · 2022 · cited 11× · PMID 35326641 · DOI 10.3390/cancers14061490 -
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.
Kegyes D, Tat A, Vizitiu AS, Vazar-Tripon D, et al · · 2025 · cited 6× · PMID 40804253 · DOI 10.1038/s41420-025-02678-4 -
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM, Ho VT, Garcia JS. · · 2024 · cited 6× · PMID 38571944 · DOI 10.3389/fimmu.2024.1359113
Verify or expand the search:
- PubMed search for NCT04809181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
Other First Affiliated Hospital of Zhejiang University trials
Trials by the same sponsor.
- NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
- NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
- NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04809181 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
- Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing